alized disorder primarily affecting exocrine glands and the pulmonary and gastrointestinal systems (9) . The major clinical findings include abnormally high sodium and chloride concentrations in sweat, pancreatic exocrine insufficiency, and chronic progressive obstructive and destructive pulmonary disease. The prognosis is poor and death usually occurs before or in early adulthood, most often as a result of respiratory failure (9) . The primary biochemical defect in this lethal disease is unknown and no adequate biochemical marker for detecting heterozygous carriers is yet available.
Many biochemical studies have investigated the presence of factors, abnormal proteins and/or altered enzymes in tissues derived from patients with CF ( I , 7, 9) . Numerous studies have been done on lysosomal glycosidases but few consistent findings have been reported. Among the most reproducible of the findings on glycosidases is the significant elevation of a-D-glucosidase activity in CF tissues (2) (3) (4) (5) (6) (7) . In a previous study we confirmed the fact that neutral a-D-glucosidase activity is significantly elevated in CF sera (2) . In addition, we demonstrated that this increased activity was not due to 1) increased stability upon storage at -20" C, 2) the presence of activators in CF sera or inhibitors in control sera, or 3) kinetic differences of the a-Dglucosidases. The major apparent difference between CF and control sera a-D-glucosidases was revealed in isoelectric focusing studies which indicated that significantly less CF a-D-glucosidase activity was associated with enzymatic forms with pI's below 4.8.
In the present investigation additional studies have been performed on serum a-D-glucosidase from patients with CF and from patients with chronic pulmonary disease (without CF) to determine the specificity of the a-D-glucosidase alteration(s). The results indicate that both groups of patients have elevated serum a-D-glucosidase activity levels and similarly abnormal isoelectric focusing profiles, suggesting that the abnormalities may be secondary to chronic pulmonary disease. ALHADEFF ET AL.
MATERIALS AND METHODS
General. All procedures were carried out at 0-4" C unless 
<
Hahnemann University, Philadelphia, PA (see Table 1 ). Sera g were prepared from whole blood as follows: the whole blood was (in citrate-phosphate buffer). The reactions were run for 75-180 min, terminated with 1.0 ml 0.085 M glycine-carbonate buffer (pH 9.7), and fluorescence read on a Turner fluorometer. These activity readings were corrected for tissue and substrate blanks. The assay was linear for amount of protein and for incubation time under the above conditions. A unit of a-D-glucosidase activity was defined as the amount of enzyme necessary to hydrolyze 1 nmol of substratelh at 37" C.
Isoelectric focusing. Isoelectric focusing was performed essentially as previously described (2) using 2% (v/v) pH 4-6 ampholytes (LKB Produkter) in a gradient of 0-67% (w/v) sucrose on a 40.0 ml analytical column. Control and patient sera (0.3-3.0 ml) were subjected to isoelectric focusing at a starting voltage of 600 V and current of 2.5-7.0 mA. After focusing for 13-20 h (until constant current is achieved) the column was eluted, fractions (approximately 0.3 ml) were collected, their pH values determined on a Beckman digital pH meter, and 50 r l aliquots were assayed for neutral a-D-glucosidase activity. The isoelectric focusing profiles are plotted as amount of a-D-glucosidase activity (unitslml) versus pI of the various forms of the enzyme.
Categorization ofpatients The diagnosis of CF was established on the basis of characteristic clinical features and an elevated sweat chloride concentration obtained by the quantitative pilocarpine iontophoresis method. All patients were clinically stable at the time blood samples were drawn. Their ages ranged from 19-40 yr and the clinical severity of their illness, using a standardized system of scoring (8), ranged from 34-90 (0 = worst; 100 = best). Patients were chosen to include those with and without pancreatic insufficiency and with and without diabetes mellitus. One patient had biliary cirrhosis and one had multiple chronic inflammatory giant pancreatic cysts. All were receiving oral antibiotics and those with pancreatic insufficiency were taking pancreatic enzyme supplements.
Statistical tests. The nonparametric Mann-Whitney U test was employed to determine if the mean serum a-D-glucosidase activity levels were significantly different in the three groups (CF, chronic lung disease, and normal control). Table 1 summarizes the host information (e.g. diagnosis, sex, age), clinical scores, and serum a-D-glucosidase activities of the patients investigated in the present study. The mean serum a-Dglucosidase activity was somewhat higher in the patients with CF (15.8 & 8.7 unitslml) than in the chronic lung disease patients (9.2 + 5.7 unitslml) and a wide range of activity was found for both groups. These mean activities are both significantly higher (p < 0.002) than the mean a-D-glucosidase activity (2.7 f 0.8 unitslml) of 15 normal controls found in our previous study (2) . Figure 1A depicts a representative isoelectric focusing profile of serum a-D-glucosidase from a normal control. Two major areas of approximately equal enzymatic activity are observed centered around pI values of 4.0 and 7.0. As in our previous study (2) , a large percentage of the total recovered a-D-glucosidase activity in control sera exists below a pI value of 4.8. In contrast, Figure 1 B and C indicate that patients with CF both with (patient AG) and without (patient EP) pancreatic insufficiency, respectively, have serum a-D-glucosidase profiles with little activity below pI values of 4.8. These profiles are representative of the great majority of patients with CF investigated in the present and previous study (2) . Three of the patients with CF (EG, GC, and JD, Table 1 ) had serum a-D-glucosidase profiles very similar to normal controls (as in Fig. 1A ) with large relative amounts (r 50%) of total recovered activity below a pI value of 4.8. Two of these patients (EG and GC) also have diabetes mellitus but this is unlikely to account for a normal-appearing a-D-glucosidase profile since a third patient with CF (JC) with diabetes mellitus gave the characteristic atypical profile. Figure 2 depicts serum a-D-glucosidase profiles of three pathological controls, i.e. patients without CF but with chronic pulmonary disease. The profile in Figure 2A of a patient (DM) with asthma is representative of seven asthma patients investigated and the profile in Figure 2B (patient RT) is representative of the four bronchiectasis patients investigated. The profile from a patient (RB) with chronic bronchocentric granulomatous lung disease is given in Figure 2C . Inspection of all the profiles in Figure 2 indicates that the great majority of enzymatic activity in these pathological controls occurs at pI values greater than 4.8 (as it does in the CF profiles). Atypical a-D-gluwsidase profiles (similar to those in Fig. 2) were found for 12 of 13 of the patients with chronic pulmonary disease.
RESULTS

DISCUSSION
Several previous studies have documented abnormalities in the activity levels and/or properties of a-D-glucosidase derived from CF tissues (2-7). In one study isoelectric focusing revealed consistently decreased relative amounts of a-D-glucosidase activity with acidic pI values (5 4.8) in CF sera when compared to control sera (2) . In the present investigation this earlier study has been extended to include 14 additional patients with CF as well as 13 pathological controls suffering from chronic pulmonary disease. The chronic pulmonary disease patients without CF were included to determine the specificity of the a-D-glucosidase alterations in CF sera since essentially all patients with CF suffer from chronic lung disease (9) . As in the previous study, increased a-D-glucosidase activity levels and altered isoelectric focusing profiles with decreased relative amounts of acidic forms have been found in CF sera. These a-D-glucosidase alterations do not appear to be related to any of a number of CF patient host factors (e.g. sex, age, severity of disease, presence of pancreatic insufficiency, or diabetes mellitus) but the data are too limited for any definite conclusions in this regard.
The chronic pulmonary disease patients without CF had an increased mean serum activity level of a-D-glucosidase but not as high as in the patients with CF. These patients also exhibited altered a-D-glucosidase profiles (with decreased amounts of activity with acidic pI values) similar to those seen in sera from patients with CF. As a matter of fact, the profiles in the patients with chronic pulmonary disease were more consistently altered than in the patients with CF. Only one (RW) of 13 of these patients had a serum a-D-glucosidase profile with a large amount (r 50%) of activity with pI values below 4.8. Interpretation of this profile is complicated by the fact that this patient has immune deficiency in addition to bronchiectasis. The findings in the pathological controls suggest that the alterations of serum a-D-glucosidase in patients with CF may be secondary to chronic pulmonary disease. The alterations are unlikely to be secondary to the pancreatic insufficiency found in the great majority of patients with CF since the three patients without pancreatic insufficiency also exhibited increased a-D-glucosidase activity levels and altered isoelectric profiles.
The results of the present investigation emphasize the importance of including appropriate pathological controls in addition to normal controls when doing biochemical studies on CF. Since appropriate pathological controls are often not included in studies on CF, it is likely that many of the biochemical abnormalities found in tissues derived from patients with CF are not specific for CF but are secondary to chronic disease.
ABSTRACT. To determine day-to-day variability in respiratory pattern, we obtained 188 comparisons of pneumograms performed during two successive 24-h intervals. The respiratory pattern values calculated were total duration of brief apnea (apnea density), periodic breathing episodes, longest apnea, number of apneas >11 s, and number of apneas >15 s. For day 1 values for apnea density, periodic breathing, and longest apnea which were within the 90th percentile for normal infants at age 1 month, day 2 values fell outside that range in 4.3,3.5, and 18% of comparisons, respectively. There was a systematic tendency for the day 2 values to be less than the day 1 values. For each parameter, the day 2 range was lower, the slope of the day 2 versus day 1 regression line was significantly less than 1 ( p < 0.01) and the y-intercept was significantly greater than zero ( p < Two-channel recordings of ECG and thoracic impedence (pneumograms) are commonly performed in infants with symptomatic apnea and in asymptomatic infants considered to be at increased risk for SIDS. Based primarily on single 24-h recordings, Kelly and coworkers (3, 4) documented significantly greater periodic breathing in A01 infants and in subsequent siblings compared to control infants. In earlier reports, we confirmed the presence of pneumogram abnormalities in A01 compared to control infants (2) , and documented improvement in these abnormalities with theophylline (1) .
Investigators have used various methods for printing and displaying pneumogram recordings and different criteria for Dneumoeram interoretation. In addition to uncertaintv as to the bpper n&al limii for the various calculated there are no reported studies of day-to-day variability in pneumogram results. Although two previous pneumogram studies in normal infants (2,5) did include some serial recordings, variability could
